

Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Case Library)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Venetoclax is FDA approved for acute myeloid leukemia (AML) in which setting?**
 - a. For patients eligible for intensive chemotherapy
 - b. In combination with 7 + 3 induction therapy
 - c. For patients with relapsed or refractory AML
 - d. In combination with a hypomethylating agent or low-dose cytarabine for patients 75 years or older
- 2. Which of the following drug types best describes enasidenib?**
 - a. Bcl-2 inhibitor
 - b. IDH2 inhibitor
 - c. FLT3 inhibitor
 - d. JAK2 inhibitor
- 3. Which of the following drug types best reflects the mechanism of action of gilteritinib?**
 - a. Bcl-2 inhibitor
 - b. IDH1/2 inhibitor
 - c. FLT3 inhibitor
 - d. JAK2 inhibitor
- 4. Luspatercept is approved by the FDA for the treatment of anemia in which of the following patients?**
 - a. Those with very-low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts whose disease has progressed on an erythropoiesis stimulating agent and required 2 or more RBC units
 - b. Those with high-risk MDS whose disease has progressed on an erythropoiesis stimulating agent and required 2 or more RBC units
 - c. Luspatercept has not been assigned an FDA indication for MDS